Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
06:30am, Wednesday, 09'th Nov 2022
CAMBRIDGE, Mass.
Sage Therapeutics, Inc. (SAGE) Q3 2022 Earnings Call Transcript
02:38pm, Tuesday, 08'th Nov 2022
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Helen Rubinstein - Director, IR Barry Greene - Chief Executive Officer Kimi Igu
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
12:45pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.94% and 3.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
09:02am, Tuesday, 08'th Nov 2022
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.94% and 3.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
02:01pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
06:30am, Tuesday, 25'th Oct 2022
CAMBRIDGE, Mass.
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
01:15pm, Monday, 03'rd Oct 2022 Zacks Investment Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can
Should WisdomTree U.S. SmallCap ETF (EES) Be on Your Investing Radar?
10:20am, Monday, 05'th Sep 2022 Zacks Investment Research
Style Box ETF report for EES
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
06:30am, Friday, 02'nd Sep 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Is WisdomTree U.S. SmallCap ETF (EES) a Strong ETF Right Now?
10:20am, Tuesday, 30'th Aug 2022 Zacks Investment Research
Smart Beta ETF report for EES
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
10:50am, Thursday, 11'th Aug 2022
The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.
Sage Therapeutics, Inc. (SAGE) CEO Barry Greene on Q2 2022 Results - Earnings Call Transcript
12:25pm, Tuesday, 02'nd Aug 2022
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Helen Rubinstein - IR Barry Greene - CEO Albert Robichaud - Chief Scientific Offi
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
11:45am, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.39% and 14.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
09:05am, Tuesday, 02'nd Aug 2022
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.39% and 14.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
